Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04985565
Other study ID # 2020-0673
Secondary ID NCI-2021-0202220
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 27, 2021
Est. completion date October 20, 2025

Study information

Verified date March 2024
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial studies the effects of a dietary intervention prior to surgery (neoadjuvant) in patients with intermediate risk prostate cancer. Changing your diet before surgery may help to improve overall health. Information from this study may help researchers better understand the influence of diet on the outcomes of patients with intermediate prostate cancer.


Description:

PRIMARY OBJECTIVE: I. To determine the feasibility of a neoadjuvant feeding study prior to radical prostatectomy in a racially diverse group of men diagnosed with intermediate risk prostate cancer, defined as the percentage of patients who enter the pre-intervention equilibration period and begin the dietary intervention. SECONDARY OBJECTIVES: I. Determine the tolerance of Mediterranean diet as defined by compliance with diet of 70% or greater total calories consumed during study period from the Mediterranean diet. II. Determine the effects of controlled dietary interventions on metabolic parameters. III. Determine the total number of potentially eligible patients who are approached by study coordinators and enter the equilibration period. IV. Determine the effects of controlled dietary interventions on the fecal microbiome. V. Create a well annotated bank of clinical data and samples, including but not limited to periprostatic fat, for use in future research and analysis. VI. Examine the safety of controlled dietary interventions in patients with a diagnosis of prostate cancer. VII. Determine changes in Cav-1-sphingolipid signature following Mediterranean diet consumption. VIII. Compare Cav-1-sphingolipid levels following dietary interventions in with a separate cohort of men who do not undergo pre-operative dietary intervention. OUTLINE: Patients participate in the Mediterranean diet for 6 days per week for 4 weeks before undergoing standard of care radical prostatectomy. After completion of study treatment, patients are followed up at 4-8 weeks.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 12
Est. completion date October 20, 2025
Est. primary completion date October 20, 2025
Accepts healthy volunteers No
Gender Male
Age group 30 Years to 75 Years
Eligibility Inclusion Criteria: - Histologically confirmed adenocarcinoma of the prostate that is localized based on prostate magnetic resonance imaging (MRI) and meets National Comprehensive Cancer Network (NCCN) intermediate risk criteria (as follows): - Clinical T2b-T2c or lower disease - Gleason Grade group 2 or 3 on biopsy - Prostate specific antigen (PSA) =< 20 ng/mL - Desires radical prostatectomy (open or robotic) for prostate cancer management and is a surgical candidate as determined by the treating urologic oncologist - Adult men > 30 and < 75 years old (African American or non-Hispanic white) - Meet one of the following criteria for overweight or obesity: - Body Mass Index (BMI) between 26 and 39 - Waist circumference >= 40 inches - Willingness to exclusively consume all the provided meals - Willingness to comply with all study procedures and scheduled visits - Reside in the greater Houston/outlying areas and/or willing to travel for study-related visits at MD Anderson Exclusion Criteria: - Major dietary restrictions or food allergies - Food aversions or preferences that preclude following a Mediterranean diet, such as unwillingness to eat vegetables, grains, animal products or fish - Medical contraindications to the intervention diet as determined by the treating physician - Current self-reported smoker or heavy drinker (defined as >14 drinks per week) or current self-reported illicit drug use - Prostate cancer that meets NCCN high and very high risk criteria (as follows): - pT3a or higher disease - Grade group 4 or 5 adenocarcinoma of prostate - PSA > 20ng/mL

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Dietary Intervention
Participate in Mediterranean diet
Procedure:
Radical Prostatectomy
Undergo standard of care radical prostatectomy

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of conducting a controlled feeding study in prostate cancer patients with intermediate risk disease Feasibility is defined as >= 25% of patients who enter the equilibration period initiating the dietary intervention. Up to 1 year from site initiation
Secondary Tolerance of Mediterranean diet Defined as compliance of 70% or greater total caloric intake consumed from the provided Mediterranean diet meals. Will estimate the number of patients that were compliant along with the 95% confidence intervals. Up to 1 year
Secondary The effects of controlled dietary interventions on metabolic parameters As measured using metabolomics (Cav-1-signature score) and nuclear magnetic resonance (NMR) spectroscopy (using Nightingale platform). Paired t-test will be used to compare the metabolic parameters changes (pre- and post- dietary intervention) in untargeted mass spectrometry-based metabolite levels and NMR-based metabolite levels. Up to 1 year
Secondary The effects of controlled dietary interventions on the fecal microbiome Exploratory analysis using microbiome core. Fecal microbiome samples will be summarized using alpha diversity, computed using the inverse Simpson index, which can then be compared across time points using a paired t-test. Up to 1 year
Secondary Create a well annotated bank of clinical data and samples, including peri-prostatic fat, for use in future research and analysis Anticipate 100% participation in patients who enroll and complete diet intervention. Up to 1 year
Secondary Examine the safety of controlled dietary interventions in patients with a diagnosis of prostate cancer percentage of severe adverse reactions in patients completing the diet. Up to 1 year
Secondary Determine changes in Cav-1-sphingolipid signature following Mediterranean diet consumption Will compare the baseline Cav-1-signature score levels with the post-diet (day of surgery) levels using paired t-tests. This evaluation is exploratory in nature and will be used to guide power calculations for future studies. Up to 1 year
Secondary Determine changes in Cav-1-sphingolipid signature following dietary intervention compared to a separate cohort with no intervention Will use a two-sample t-test to compare the levels of Cav-1-sphingolipid signature score in men who undergo a dietary intervention in this protocol with subjects enrolled under the separate protocol (protocol 2020-0828, "Diet, Biomarker, and Tissue Assessment in Intermediate Risk Prostate Cancer"). Up to 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03796767 - Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer Phase 2
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT05735223 - A Prospective Study to Evaluate the Impact of Maximal Urethral Length Preservation Technique During Robotic Laparoscopic Prostatectomy on the Stretched Flaccid Penile Length and Continence N/A
Recruiting NCT04175431 - Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study Phase 2
Completed NCT05197257 - 68Ga-PSMA-11 PET in Patients With Prostate Cancer Phase 3
Withdrawn NCT03982173 - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors Phase 2
Terminated NCT02491411 - Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel N/A
Active, not recruiting NCT02254746 - A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer N/A
Active, not recruiting NCT05496959 - 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study Phase 2
Completed NCT02940262 - Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy Phase 3
Recruiting NCT04391556 - Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma Phase 2
Enrolling by invitation NCT03503643 - Hemi-Gland Cryoablation for Prostate Cancer at UCLA
Recruiting NCT05832086 - Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes Phase 2
Suspended NCT05064111 - Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy
Not yet recruiting NCT04031378 - Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer Phase 2
Recruiting NCT02600156 - Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors N/A
Recruiting NCT05726292 - A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer Phase 2
Recruiting NCT04423211 - Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging Phase 3
Terminated NCT03718338 - Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma
Terminated NCT02564549 - MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca N/A

External Links